Democritus University of Thrace (DUTH)
Γενετικοί παράγοντες που καθορίζουν την εκδήλωση του βρογχικού άσθματος σε παιδιά καθώς και την ανταπόκριση των ασθενών αυτών στη φαρμακευτική αγωγή
Abstract
dc:descriptionChildhood asthma is a chronic airway inflammatory disease resulting from the interaction between environmental and genetic factors. Atopy, which is characterized by increased levels of specific IgE against common environmental allergens, is considered one of the strongest predisposing factors for childhood asthma. Regarding therapy, inhaled corticosteroids (ICS) have been recognized as the preferred long-term control therapy in patients with asthma, including children of all ages. Notably, high inter-individual variability in response to ICS treatment is found, with up to 40% of patients with asthma not responding sufficiently. In addition, family studies have shown genetic heritability in sensitization to allergens, response to glucocorticoid therapy and asthma control level.Nitric oxide synthase (NOS) enzymes have important role in regulating airway inflammation in asthmatic children. Genetic loci that encode nitric oxide synthase (NOS) enzymes affect nitric oxide (NO) formation, which plays a key role as an inflammatory mediator in the airways. Furthermore, the vitamin D pathway has recently emerged as a new potential component of asthma and allergy susceptibility. Vitamin D levels have been suggested as a marker of disease severity in asthmatic children. The functions of vitamin D depend also on individual Vitamin D Receptor (VDR) and Vitamin D Binding Protein (VDBP) genetic variability. Serotonin (5-HT) has also been reported to regulate the airway inflammation and bronchial hyperreactivity in asthma pathophysiology.The aim of this study was to investigate the possible association of genetic polymorphisms of NO, vitamin D and serotonin pathways with childhood asthma susceptibility, the sensitization of asthmatic children to common inhaled allergens, the asthmacontrol level, and the response to inhaled corticosteroids in combination with LABAs.Our study population consisted of 193 children diagnosed as having asthma and 96 healthy controls all of Greek origin. The sensitization to common allergens was defined according to skin prick test reactions for 8 aeroallergens. Asthma control level was defined according to GINA criteria and the C-ACT questionnaire for asthma control level assessment for all asthmatic children aged 5-12 years old not receiving anti-asthmatic treatment at least 6 months prior to their enrollment in this study. The response to inhaled corticosteroids (ICS) with long acting b2-agonists (LABAs) was recorded as % change in FEVi over baseline. Children who had shown improvement more than 7.5% of predicted FEVi over baseline at least once during the 12 month treatment period were classified as responders (FEVi change >7.5%). Healthy control group was consisted of children without personal or family history of asthma or atopy.The total of children participating in this study was genotyped for the following polymorphisms: G894T and -786T/C of endothelial nitric oxide synthase gene (eNOS), Ser608Leu of inducible nitric oxide synthase gene (iNOS), rs7975232 of Vitamin D receptor gene (VDR), rs7041 and rs4588 of Vitamin D binding protein gene (VDBP), 5-HTTLPR of 5-HT transporter gene (5-HTT), and 102T/C of 2A serotonin receptor gene (5-HTR2A). Genomic DNA was extracted from white blood cells and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were used for identification of eNOS G894T and -786T/C, iNOS Ser608Leu, VDR rs7975232, VDBP rs7041 and rs4588, 5-HTT 5-HTTLPR, and 5-HTR2A 102T/C polymorphisms.According to our results, all the studied polymorphisms were not associated with childhood asthma susceptibility. However, the 894GG genotype was more frequent (68.6%) in asthmatic children sensitized to Olea europeae compared with asthmatic children non-sensitized (43.0%o) (p=0.004). Similarly, the frequency of -786TT genotype was higher in asthmatic children sensitized to Olea europeae (51.0%) than in non-sensitized (31.7%) asthmatic children to this allergen (p=0.035). For the Parietaria judaica and mixed grass, the frequency of -786C allele carriage was associated with protection from sensitization to Parietaria judaica and mixed grass in asthmatic children (p=0.021 and p=0.017, respectively). Also, the VDR Apal CC genotype was associated with protection from sensitization to Parietaria judaica (p=0.055), Mixed grass (p=0.043), and Alternaria alternate (p=0.022) and the rs4588 A A genotype was associated with sensitization to Dermatophagoides pteronys sinus (p=0,015).For asthma control level, in asthmatic children, those with the VDR Apal CC genotype had significantly higher C-ACT score compared with asthmatic children carrying the AA/AC VDR Apal genotypes (p=0.015). The frequency of VDR Apal CC genotype was significantly higher in controlled asthma group than uncontrolled asthma group according to C-ACT (26.2% vs 0.0%, p=0.001) and GINA (33.3% vs 9.1%, p=0.017) classifications. Also, VDR Apal CC genotype was negatively associated with limitation in daily activities because of asthma (p=0.006).Regarding pharmacogenetic results, among asthmatic children, 894TT carriers had much more pronounced change in FEVi than 894GG carriers (21.9±3.8% versus 1.6±1.9%, pO.001). In responders (FEVi change >7.5%), frequency of 894TT genotype was significantly higher than in non-responders (26.2% vs 2.6%, pO.001). Also, carriers of 894T allele were almost 5 times more likely to respond to ICS than 894GG carriers (OR=5.1, p=0.001). Results with -786T/C polymorphism, alone or combined with G894T polymorphism, were less clear and in most cases non significant.In conclusion, eNOS G894T and -786T/, as well as VDR Apal and VDBP rs4588 polymorphisms, were associated with sensitization to common aeroallergens in asthmatic children. Furthermore, the VDR Apal polymorphism was significantly associated with asthma control level in asthmatic children 5-12 years old not receiving any anti-asthmatic treatment. Regarding pharmacogenetics, the eNOS 894TT genotype was significantly associated with response to ICS plus LABA in asthmatic children.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Iordanidou, Maria
- Ιορδανίδου, Μαρία
Subjects
dc:subject × 32- Παιδικό βρογχικό άσθμα
- Μονοξείδιο αζώτου (NO)
- Βιταμίνη D
- Σεροτονίνη
- Πολυμορφισμός
- Έλεγχος άσθματος
- Φαρμακογενετική άσθματος
- Ευαισθητοποίηση σε αλλεργιογόνα
- Childhood bronchial asthma
- Nitric oxide (NO)
- eNOS
- iNOS
- Vitamin D
- VDR
- VDBP
- Gc
- Serotonin
- 5-HT
- 5-HTT
- 5-HTP2A
- Polymorphisms
- Asthma control
- C-ACT
- GINA
- Asthma pharmacogenetics
- Sensitization to allergens
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35094